Abstract: Vaccine composition containing IL-15 for active immunization to treatment diseases related to over-expression of this cytokine. The technical aim pursued in this invention is to inhibit IL-15 activity through development of a therapeutic vaccine which elicits IL-15 neutralizing antibodies in the immunized host. IL-15 can be presented in this vaccine composition either alone or coupled to a carrier such as the P64k protein with a vaccine adjuvant such as Aluminum hydroxide. Besides, this invention is related to the use of this vaccine for treatment of Rheumatoid arthritis and other IL-15 over-expressing related diseases, and leukemia, where this cytokine acts as a growth factor.

Abstract: Compositions of non-racemic mixtures of d- and l-methadone and a method of treating pain using the composition. The composition is especially useful for treating pain of mixed origin. For predominantly neuropathic pain, a mixture of predominantly d-methadone, up to about 90%, is used. For predominantly somatic pain, a mixture of predominantly l-methadone, up to about 90%, is used. The non-racemic mixture of d- and l-methadone may be further combined with a pharmacologically effective amount of a nonopioid component. In another aspect of the invention, the methadone can be combined with an opioid antagonist such as naloxone, naltrexone, or the like.

Abstract: Methods for treating and/or protecting H. pylori infection are described. The methods utilize non-mucosal administration of an effective amount of one or more H. pylori antigens.

Abstract: Light emitting compounds of the formula: wherein R1 is a light-emitting moiety and R2 is a VIP-based peptide, fragment, derivative or analog thereof, said peptide being linked at an amino acid position to (C—X), wherein (C—X) is selected from the group consisting of C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties, wherein said compound exhibits substantial biological activity in the presence of a receptor having affinity for VIP-based peptides.

Abstract: Light emitting compounds of the formula: wherein R1 is a light-emitting moiety and R2 is a substance P-based peptide, fragment, derivative or analog thereof, said peptide being linked at an amino acid position to (C—X), wherein (C—X) is selected from the group consisting of C═O, C═S, CH(OH), C═C═O, C═NH, CH2, CH(OR), CH(NR), CH(R), CR3R4, and C(OR3)OR4 where R, R3, and R4 are alkyl moieties or substituted alkyl moieties, wherein said compound exhibits substantial biological activity in the presence of a receptor having affinity for substance P-based peptides.

Abstract: Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a resultant promotion of the regenerative growth of the axon is detected.

Abstract: A method for treating an addiction disorder (such as an addiction to or dependency on stimulants, nicotine, morphine, heroin, other opiates, amphetamines, cocaine, and/or alcohol) in a patient is disclosed. The method includes administering to the patient a first &agr;3&bgr;4 nicotinic receptor antagonist and administering to the patient a second &agr;3&bgr;4 nicotinic receptor antagonist. The second &agr;3&bgr;4 nicotinic receptor antagonist is different than the first &agr;3&bgr;4 nicotinic receptor antagonist, and the first &agr;3&bgr;4 nicotinic receptor antagonist and the second &agr;3&bgr;4 nicotinic receptor antagonist are administered simultaneously or non-simultaneously. Compositions which include a first &agr;3&bgr;4 nicotinic receptor antagonist and a second &agr;3&bgr;4 nicotinic receptor antagonist are also described.

Abstract: Provided are compounds of the formula (1): wherein R′ is hydrogen, methyl or NH2C(O)CH2—; R″ and R′″ are independently methyl or hydrogen; R adn Ry are independently hydroxy or hydrogen; R1 is hydroxy, hydrogen, or hydroxysulfonyloxy; R7 is hydroxy, hydrogen, hydroxysulfonyloxy or phosphonooxy; R2 is a novel acyl side chain. Also provided are novel formulations, methods of inhibiting fungal and parasitic activity, and a process for preparing dideoxy (R=H) forms of the compounds.

Abstract: The present invention relates to the use of a composition comprising an oil with a high content of essential fatty acids of &ohgr;3 and &ohgr;6 type, preferably blackcurrant seed oil, and at least one compound selected from &bgr;-carotene, lycopene, tocopherol and its derivatives, tocotrienols and their derivatives, ascorbic acid and nicotinamide, as a nutritional supplement intended for preventing and/or combating the harmful effects of xenobiotics on the skin, in particular on the skin's immune system.

Abstract: This invention relates to a pharmaceutical composition comprising a combination of a tramadol material and an anticonvulsant drug and to the pharmacological use of the composition in treating conditions of pain and neurologic or psychiatric disorders. The composition produces a combination product having improved properties, requiring less of each ingredient and producing a synergistic effect.

Abstract: Disclosed are compositions for promoting the production of laminin 5 in epidermic cells which contain a lysophospholipid having a C14-22 fatty acid residue or a preparation derived from soybeans as an active ingredient and which can be used in the fields of cosmetics and dermatology. These compositions may be used especially for the purpose of potentiating the skin.

Abstract: The present invention provides therapeutically effective amounts of 6MNA prodrugs. The pharmaceutical composition comprises wherein R is H or COR′, wherein R′ is selected from the group consisting of C1 to C6 alkyl, (CH2)m O(CH2)n, (CH2)m(OC2H4)p O(CH2)n, (CH2)m(OC2H4)p, (OCH2H4)p ONO2 and (OCH2H4)p O(CH2)n wherein m is an integer from 2 to 4, and n and p are integers from 1 to 4. Alternatively, R is a therapeutic moiety.

Abstract: A tooth coating composition contains shellac, solvent for the shellac, and mica titanium as the main constituents. The coating provided on teeth with such composition is excellent in its drying property, durability, color tone, and easiness of removal thereof. The content of the shellac in the whole composition is preferably from 6 to 12% by weight and the content of the mica titanium is preferably from 3.5 to 16% by weight.

Abstract: A pharmaceutical composition suitable for enhancing muscular anabolism contains, per daily dose, at least 5 mg of anabolic initiators comprising anabolic growth factors, at least 0.12 g of protein equivalents of anabolic substrates and at least 3 g of anabolic facilitators comprising at least 1 g of creatine or its functional analog. The anabolic initiators may be derived from a non-denatured animal protein, non-denatured being defined as having an F0 of less than 3.0.

Abstract: Disclosed is a method for promoting bile secretion, which comprises administering an effective amount of a certain 15-keto-prostaglandin compound to a subject having a disease or condition associated with bile secretion deficient. Also disclosed is a method for treatment of a liver to be transplanted in a liver transplantation process, which comprises contacting the liver with a liquid composition comprising the 15-keto-prostaglandin compound as above.

Abstract: A two component desensitizing dentifrice composition is disclosed which comprises a first dentifrice component containing a desensitizing potassium salt such as potassium nitrate and an alkali metal compound such as NaOH and a second dentifrice component containing a desensitizing stannous salt source such as stannous, the first and second dentifrice components being maintained separate from the other until dispensed for application to teeth.

Abstract: A method of reducing or inhibiting mucositis in a patient, which includes administering an inflammatory cytokine inhibitor or a mast cell inhibitor, or a combination thereof, is disclosed.

Abstract: A composition for use as a dental impression material including a polymerizable telechelic oligomer or polymer curable by ring-opening metathesis polymerization, a filler system, and a ruthenium carbene complex catalyst, whereby the catalyst initiates ring-opening metathesis polymerization of the composition. The invention includes a paste/paste system in which a base paste includes the polymerizable telechelic oligomer or polymer and a filler system and in which a catalyst paste includes the catalyst dissolved in an inert solvent and a filler system. The telechelic oligomer or polymer may be, for example, a polydimethylsiloxane end-functionalized with norbornenyl groups. The catalyst may be, for example, a ruthenium carbene complex with a ligand having a basicity higher than tricyclohexylphosphine. The composition of the present invention exhibits reduced sensitivity to sulfur impurities.

Abstract: The present invention is directed towards a topical composition for the treatment of acne comprising water, an organic peroxide, an alpha hydroxy acid, a moisturizer, an isosorbide and a detergent. This invention also is directed to a method of making the composition of this invention. The method involves (1) heating water to between 60° C. and 70° C.; (2) adding a detergent base to the water and mixing the solution; (3) cooling the solution and adding an alpha hydroxy acid, an isosorbide and sodium pyrollidone carboxylate; (4) continuing to cool the solution to between 25° C. and 35° C. and then adding benzoyl peroxide and a preservative to the solution; (5) mixing and milling the product until smooth; and (6) adjusting the pH of the product to a pH of 3-5 with a base. This invention also is directed towards a method for treating a patient afflicted with acne by applying the composition of this invention to the affected areas of the patient's skin.

Abstract: Compositions and methods are provided for prophylactic or therapeutic treatment of balance impairments involving neuronal damage, loss, or degeneration, preferably of vestibular ganglion neurons, in an animal by administration of an effective amount of a trkB or trkC agonist, particularly a neurotrophin, more preferably NT-4/5.